{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-027984","form_type":"8-K","ticker":"OSRH","cik":"0001840425","company_name":"OSR Holdings, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.485888+00:00","generated_at":"2026-05-15T11:55:29.768798+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OSR Holdings discloses Pexa-Vec license talks and potential SillaJen controlling stake","bullets":["Vaximm in active negotiations with SillaJen to license Pexa-Vec, a Phase 2 oncolytic immunotherapy for renal cell carcinoma.","OSR Holdings held preliminary verbal talks to acquire ~16% controlling stake in SillaJen (KOSDAQ:215600).","No binding term sheet, letter of intent, or definitive agreement exists for either matter.","Disclosed to comply with Regulation FD after inadvertent reference during March 13 analyst call."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-027984","json":"https://secwatch.observer/filing/0001213900-26-027984.json","markdown":"https://secwatch.observer/filing/0001213900-26-027984.md","text":"https://secwatch.observer/filing/0001213900-26-027984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026027984/0001213900-26-027984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000121390026027984/ea0281786-8k_osr.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:55:29.768798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}